All patients | Leiomyo-sarcomas | Undifferentiated pleomorphic sarcoma | Liposarcomas | Vascular sarcomas | Fibroblastic/myofibroblastic sarcomas | Nerve sheath sarcomas | Rhabdomyo-sarcomas | Synovial sarcomas | Others/NOS | |
---|---|---|---|---|---|---|---|---|---|---|
N | 4274 | 922 | 652 | 554 | 357 | 227 | 106 | 98 | 49 | 1309 |
Sex (n, %) | ||||||||||
Male | 2103 (49.2) | 307 (33.3) | 390 (59.8) | 329 (59.4) | 195 (54.6) | 122 (53.7) | 64 (60.4) | 43 (43.9) | 28 (57.1) | 625 (47.8) |
Female | 2171 (50.8) | 615 (66.7) | 262 (40.2) | 225 (40.6) | 162 (45.4) | 105 (46.3) | 42 (39.6) | 55 (56.1) | 21 (42.9) | 684 (52.2) |
Race | ||||||||||
White | 3729 (87.3) | 783 (84.9) | 576 (88.3) | 499 (90.1) | 309 (86.6) | 203 (89.4) | 96 (90.6) | 82 (83.7) | 43 (87.8) | 1138 (86.9) |
Black | 337 (7.9) | 106 (11.5) | 46 (7.1) | 23 (4.2) | 21 (5.9) | – | – | – | – | 106 (8.1) |
Other | 197 (4.6) | 31 (3.4) | 26 (4.0) | 32 (5.8) | 25 (7.0) | – | – | – | – | 63 (4.8) |
Age at advanced diagnosis | ||||||||||
Mean (SD) | 77.8 (7.3) | 76.8 (7.2) | 79.4 (7.2) | 77.5 (7.1) | 78.2 (7.5) | 77.8 (7.1) | 77.7 (7.6) | 76.8 (7.3) | 74.1 (6.5) | 78.0 (7.4) |
Median | 77.4 | 76.1 | 79.7 | 76.6 | 77.9 | 77.8 | 77.3 | 76.6 | 73.5 | 77.5 |
Min, Max | 65.0, 104.1 | 65.0, 102.9 | 65.1, 99.3 | 65.1, 96.8 | 65.6, 101.8 | 65.7, 97.4 | 65.5, 95.9 | 65.3, 95.3 | 65.7, 91.0 | 65.1, 104.1 |
Pre-index date Charlson Comorbidity Index (CCI) scorea | ||||||||||
Mean (SD) | 2.8 (2.3) | 2.5 (2.2) | 2.8 (2.4) | 2.8 (2.3) | 2.9 (2.7) | 2.8 (2.2) | 2.8 (2.3) | 2.6 (2.1) | 3.0 (2.3) | 2.8 (2.4) |
Median | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 |
Min, Max | 0.0, 15.0 | 0.0, 14.0 | 0.0, 15.0 | 0.0, 12.0 | 0.0, 12.0 | 0.0, 11.0 | 0.0, 10.0 | 0.0, 9.0 | 0.0, 8.0 | 0.0, 15.0 |
Stage of disease at initial diagnosis of STS (n, %) | ||||||||||
Localized | 1731 (40.5) | 345 (37.4) | 379 (58.1) | 260 (46.9) | 150 (42.0) | 121 (53.3) | 36 (34.0) | 25 (25.5) | 18 (36.7) | 397 (30.3) |
Regional—direct extension only | 938 (22.0) | 200 (21.7) | 135 (20.7) | 177 (32.0) | 62 (17.4) | 59 (26.0) | 32 (30.2) | 14 (14.3) | 11 (22.5) | 248 (19.0) |
Regional—lymph nodes involved only | 29 (0.7) | – | – | – | – | – | – | – | 0 (0.0) | – |
Regional—direct extension and lymph nodes | 37 (0.9) | – | – | – | – | – | – | – | 0 (0.0) | – |
Distant | 1539 (36.0) | 363 (39.4) | 133 (20.4) | 114 (20.6) | 138 (38.7) | 45 (19.8) | 36 (34.0) | 53 (54.1) | 20 (40.8) | 637 (48.7) |
Grade of cancer at time of initial diagnosis of STS (n, %) | ||||||||||
Well or moderately differentiated (grade 1 or 2) | 646 (15.1) | 152 (16.5) | 36 (5.5) | 239 (43.1) | 40 (11.2) | 50 (22.0) | – | – | – | 116 (8.9) |
Poorly differentiated (grade 3) | 908 (21.2) | 192 (20.8) | 151 (23.2) | 101 (18.2) | 81 (22.7) | 35 (15.4) | – | – | 16 (32.7) | 294 (22.5) |
Undifferentiated (grade 4) | 1310 (30.7) | 250 (27.1) | 228 (35.0) | 129 (23.3) | 61 (17.1) | 63 (27.8) | 28 (26.4) | 34 (34.7) | – | 510 (39.0) |
Unknown | 1410 (33.0) | 328 (35.6) | 237 (36.4) | 85 (15.3) | 175 (49.0) | 79 (34.8) | 54 (50.9) | 39 (39.8) | 24 (49.0) | 389 (29.7) |
Total follow-up time (years)b | ||||||||||
Mean (SD) | 1.7 (2.4) | 1.8 (2.2) | 2.0 (2.8) | 2.6 (2.8) | 1.1 (1.7) | 2.5 (2.7) | 1.4 (2.1) | 0.8 (1.5) | 1.4 (1.8) | 1.3 (2.0) |
Median | 0.7 | 1.0 | 0.8 | 1.5 | 0.5 | 1.6 | 0.5 | 0.3 | 0.6 | 0.5 |
Min, Max | 0.0, 12.8 | 0.0, 12.2 | 0.0, 12.3 | 0.0, 12.3 | 0.0, 12.5 | 0.0, 12.5 | 0.0, 9.9 | 0.0, 9.8 | 0.0, 8.8 | 0.0, 12.8 |